| timdarpacept (IMM01) / ImmuneOnco Biopharma |
NCT06465446: A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma |
|
|
| Not yet recruiting | 3 | 202 | NA | Tislelizumab, IMM01, Timdarpacept, Bendamustine, Gemcitabine | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Classic Hodgkin Lymphoma | 06/26 | 07/29 | | |
IMM01-04, NCT05833984: Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas |
|
|
| Recruiting | 1b/2 | 309 | RoW | IMM01, SIRPα Fc, Tislelizumab | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Solid Tumor, Classic Hodgkin Lymphoma | 02/24 | 11/24 | | |
ChiCTR1900024904: Exploratory study for IMM01 for injection in refractory or relapsed lymphoma |
|
|
| Recruiting | 1/2 | 30 | | Intravenous infusion IMM01 | Hematology Hospital, Chinese Academy of Medical Sciences; ImmuneOnco Biopharmaceuticals(Shanghai) Co., Ltd, self-pay | Lymphoma | | | | |
IMM01-02, NCT05140811: A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome |
|
|
| Recruiting | 1/2 | 126 | RoW | IMM01, IMM01 Ingection, Azacitidine, Vidaza | ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Institute of Hematology & Blood Diseases Hospital | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 02/24 | 03/24 | | |
NCT05860075: Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy |
|
|
| Terminated | 1 | 73 | RoW | IMM01, IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG1 fusion protein | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Hematologic Malignancy | 10/22 | 10/22 | | |
